Press Release

Jazz Pharmaceuticals to Acquire Celator for $1.5 Billion

June 1, 2016

San Diego – June 1, 2016 – Cooley is advising Jazz Pharmaceuticals on its $1.5 billion acquisition of Celator. The transaction will add to Jazz's portfolio the orphan drug VYXEOS, which aims to treat AML. The deal is expected to close in Q3 2016.  

Jazz Pharmaceuticals, a Cooley client since 2006, is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs. 

Celator Pharmaceuticals is an oncology-focused biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer.

The Cooley M&A team advising Jazz Pharmaceuticals includes Barbara Borden, Marya Postner, Chad Mills, Ben Beerle, Matt Silverman, Susan Walker and Edmond Lay.  

About Cooley LLP  

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.  

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.

Press Coverage:

"Jazz Pharmaceuticals Agrees to Buy Celator for About $1.5 Billion," The Wall Street Journal

"Jazz Pharmaceuticals to Buy Celator for $1.5 Billion," The New York Times 

"Jazz Pharmaceuticals Agrees to Buy Celator for $1.5 Billion," Bloomberg

"Jazz Pharmaceuticals to Buy Celator in $1.5 Billion Deal," Reuters  

"Jazz Pharmaceuticals Agrees to Purchase Celator," The Recorder

"Dealmakers: Jazz Pharma Buys Cancer Treatment Provider in $1.5B Deal with Help from Cooley, Kirkland," Daily Journal (Subscription required)

"Jazz to Acquire Celator," The American Lawyer 

"Cooley, Kirkland Lead $1.5B Jazz Pharma Deal for Celator," Law360

"Jazz Pharmaceuticals Strikes Celator Takeover Pact," The Deal

"Jazz Pharma to Buy Celator in $1.5 Bln Deal," CNBC

"Jazz Pharmaceuticals is Buying Celator for $1.5 Billion," Fortune 

"Jazz Pharma to Buy Celator for $1.5 Bln - Quick Facts," Nasdaq

"Celator Merger with Jazz Clears Antitrust Regulators," The Deal

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.